CEACAM5 and colorectal carcinoma: By exploring the pathways regulating CEA expression the authors found that a combination of cibisatamab and the WNT/β-catenin inhibitors (porcupine inhibitor LGK-974 and tankyrase inhibitor compound 21) (Fig. 3) can increase the drug sensitivity to cibisatamab in PDOs established with metastatic chemotherapy-resistant CRC patient samples.